Question · asked by 1 review
Methylnaltrexone vs placebo: Serious adverse eventsi
- Population
- people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
- Intervention
- Methylnaltrexone
- Comparison
- placebo
- Outcome
- Serious adverse eventsi
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Methylnaltrexone vs placebo Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty). Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane Headline outcomes only | RR 0.59 [0.38, 0.93] | 2 studies · 364 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.